Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study of the Zanubrutinib Given in Combination With Bendamustine and Rituximab in (Elderly or TP53 Alterations or Chemotherapy Intolerance) Patients With Newly Diagnosed Mantle Cell Lymphoma
Sponsor: Ruijin Hospital
Summary
The purpose of this study is to evaluate the efficacy and safety of Zanubrutinib given in combination with bendamustine and rituximab in (elderly or TP53 alterations or chemotherapy intolerance) patients with newly diagnosed mantle cell lymphoma.
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
23
Start Date
2023-11-15
Completion Date
2027-11-01
Last Updated
2023-11-29
Healthy Volunteers
No
Conditions
Interventions
Zanubrutinib
160 mg bid po, until disease progression, intolerance of drug toxicity or death, otherwise maintaining during the 2 years of follow-up
Rituximab
375 mg/m\^2 ivgtt, D0 of each 28-day cycle
Bendamustin
90mg/m\^2 ivgtt, D0 of each 28-day cycle
Locations (1)
Ruijin Hospital
Shanghai, Shanghai Municipality, China